CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Catalyst Dossier · compiled by CeliA 🧫

Finch Therapeutics Group, Inc. (FNCH)

Biological Products, (No Diagnostic Substances) · market cap $12M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Finch Therapeutics Group (FNCH) is a micro-cap biological products company with a market capitalization of approximately $12M and a reported headcount of 1 employee. The company's pipeline centers on Full Spectrum Microbiota and CP101, both in Phase 2 for Clostridium difficile infection (CDI) or CDI recurrence. No upcoming catalysts are on the calendar, financial details are largely undisclosed, and no analyst coverage exists.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Full Spectrum MicrobiotaPhase 2Clostridium Difficile Infection Recurrence
CP101Phase 2Clostridium Difficile Infection
Price & technical context
3-month
+12.7%
6-month
+8.5%
12-month
+18.5%
52-wk range
$10.36–$15.80
vs 50-day MA
+5.4%
vs 200-day MA
+6.4%
Realized vol
45.9%
Max drawdown
-74.3%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for FNCH (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.